Search results for "Peptic"

showing 10 items of 34 documents

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Zur Problematik der exokrinen Pankreasreaktion nach intraven�ser Tolbutamid-Belastung bei Stoffwechselgesunden und Diabetikern

1964

Die Untersuchung der exkretorischen Pankreasfunktion wahrend des Tolbutamidtestes bei 30 Stoffwechselgesunden und 13 Diabetikern lies fur die Maszahlen der absoluten Diastasewerte signifikante Unterschiede (P ≦ 0,27%) zwischen beigesteigerte exkretorische Pankrasleistung nach Tolbutamid bei Gesunden gegenuber Diabetikern hin.

Duodenal ulcerGynecologymedicine.medical_specialtybusiness.industryPeptic ulcerDrug DiscoverymedicineMolecular MedicineGeneral Medicinemedicine.diseasebusinessGenetics (clinical)Klinische Wochenschrift
researchProduct

Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension

2010

Background: Oesophagogastroduodenoscopy is currently recommended for the screening of varices in cirrhosis. In addition to the assessment of varices, oesophagogastroduodenoscopy can detect conditions that, while unrelated to portal hypertension, may require treatment. Aims: We evaluated in a large cohort of cirrhotic patients the prevalence of upper digestive findings other than oesophagogastric varices, the associations between upper gastrointestinal findings, portal hypertension and features of cirrhosis, and the incidence of new lesions in the course of a surveillance program. Methods: Analysis of the records of 611 consecutive cirrhotic patients undergoing oesophagogastroduodenoscopy fo…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPepticPortal hypertensive gastropathyAdenocarcinomaEsophageal and Gastric VaricesGastroenterologyAsymptomaticHelicobacter InfectionsPolypsStomach NeoplasmsInternal medicineHypertension PortalPrevalenceHumansMedicineEndoscopy Digestive SystemStomach UlcerVascular DiseasesAgedMetaplasiaHelicobacter pyloriHepatologymedicine.diagnostic_testbusiness.industrycirrhosisIncidence (epidemiology)GastroenterologyMiddle Agedmedicine.diseaseEndoscopyDuodenal UlcerGastritisPortal hypertensionFemalemedicine.symptombusinessVaricesDigestive and Liver Disease
researchProduct

Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly

2011

Abstract Background Proton pump inhibitors (PPI) are among the most commonly prescribed medicines and their overuse is widespread in both primary and secondary care. Inappropriate prescription is of particular concern among elderly patients, who have often multiple comorbidities and need many drugs. Methods We evaluate the appropriateness of drugs for peptic ulcer or gastro-esophageal reflux disease (GERD) in a sample of elderly patients (65 years old or older) at admission and discharge in 38 internal medicine wards between January 2008 and December 2008, according to the presence of specific conditions or gastro-toxic drug combinations. Results Among 1155 patients eligible for the analysi…

MaleDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectInappropriate PrescribingDiseaseappropriatenesselderly patientselderlyGastroenterologyCohort StudiesPharmacotherapyInternal medicineappropriateness; elderly; elderly patients; inappropriate prescription; proton pump inhibitorsPrevalenceInternal MedicinemedicineHumansMedical prescriptionpeptic ulcerAgedmedia_commonAged 80 and overSettore MED/12 - GastroenterologiaEvidence-Based Medicinebusiness.industrymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatrichedigestive system diseasesdrug therapy)inappropriate prescriptionConcomitantCohortGastroesophageal Refluxpeptic ulcer; drug therapy); Prevalence; hospitalization; elderlyGERDDrug Therapy CombinationFemaleGuideline Adherenceproton pump inhibitorsbusinessProton pump inhibitors Appropriateness ElderlyhospitalizationCohort studyEuropean Journal of Internal Medicine
researchProduct

High-definition endoscopy with i-Scan and Lugol’s solution for more precise detection of mucosal breaks in patients with reflux symptoms

2009

BACKGROUND AND STUDY AIMS: Patients with gastroesophageal reflux disease are subdivided into non-erosive (NERD) and erosive reflux disease (ERD). The newly available EPKi processor enables high-definition resolution above HDTV standard (HD+). The aim of the study was to test the efficacy of HD+ esophagogastroduodenoscopy alone and in conjunction with i-Scan (newly developed postprocessing digital filter) and chromoendoscopy (Lugol’s solution) for differentiation of reflux patients. METHODS: The distal esophagus of patients with heartburn was inspected with three imaging modalities. HD+ was followed by i-Scan and 15-mL Lugol’s solution (1.5 %). The esophagus was evaluated for mucosal breaks …

MaleLugol's Solutionmedicine.medical_specialtyNerdGastroenterologyChromoendoscopyPredictive Value of TestsInternal medicineImage Processing Computer-AssistedmedicineHumansEndoscopy Digestive SystemProspective StudiesEsophagusColoring AgentsEsophagitis PepticMucous Membranemedicine.diagnostic_testEsophagogastroduodenoscopybusiness.industryGastroenterologyRefluxHeartburnIodidesMiddle Agedmedicine.diseasemedicine.anatomical_structureGastroesophageal RefluxFemalemedicine.symptombusinessEsophagitisEndoscopy
researchProduct

The prognosis of patients having received optimal therapy for nonvariceal upper gastrointestinal bleeding might be worse in daily practice than in ra…

2010

International audience; BACKGROUND: Combination of endoscopic haemostatic and high-dose intravenous proton-pump inhibitors is considered to be the standard care for patients with acute peptic ulcer bleeding. AIM: This study assessed predictive factors of rebleeding and death in unselected patients presented to our hospital. METHODS: Consecutive patients with nonmalignant bleeding ulcers and stigmata of recent haemorrhage who received optimal treatment, between 22 August 2003 and 15 October 2007, were studied retrospectively. RESULTS: Among 140 included patients, 45 (32%) rebled and 30 received another haemostatic endoscopy, which was successful in 20 cases. In multivariate analysis, the onl…

MaleMultivariate analysisAdministration Oral2-Pyridinylmethylsulfinylbenzimidazoleslaw.inventionHospitals University0302 clinical medicineRandomized controlled trialRecurrenceRisk FactorslawOdds RatioHospital Mortality030212 general & internal medicineInfusions IntravenousPantoprazoleRandomized Controlled Trials as TopicAged 80 and overMortality rateHemostasis EndoscopicGastroenterologyMiddle AgedCombined Modality TherapyIntensive care unit3. Good healthIntensive Care UnitsPeptic Ulcer HemorrhageTreatment OutcomeInjections IntravenousFemale030211 gastroenterology & hepatologyFranceAdultmedicine.medical_specialtyRisk AssessmentYoung Adult03 medical and health sciencesInternal medicinemedicineHumansAgedRetrospective StudiesChi-Square DistributionHepatologybusiness.industryProton Pump Inhibitors[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOdds ratiomedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyConfidence intervalSurgeryLogistic ModelsUpper gastrointestinal bleedingRockall scorebusiness
researchProduct

A case of Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis.

2011

A case of a 62-year-old man with Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis that was successfully treated with a 14-day course of caspofungin is reported. The potential role of Candida infection in the pathogenesis of peptic ulcers and duodenal perforation is considered. If this role is confirmed, antifungal treatment should be included in the therapeutic armamentarium of peptic disease.

MalePeptic Ulcermedicine.medical_specialtyAntifungal AgentsVeterinary (miscellaneous)PepticPeritonitisPeritonitisApplied Microbiology and BiotechnologyMicrobiologyGastroenterologyPathogenesisEchinocandinsLipopeptideschemistry.chemical_compoundMedical microbiologyDuodenitisCaspofunginInternal medicineCandida kruseimedicineHumansDuodenal DiseasesDuodenal PerforationPeptic diseaseCandidaDuodenal perforationDuodenitibiologyPeritonitibusiness.industrySmokingCandidiasisCandida Peritonitis Duodenal perforation Duodenitis Peptic disease Caspofungin SmokingMiddle Agedmedicine.diseasebiology.organism_classificationdigestive system diseasesTreatment OutcomechemistryIntestinal PerforationCaspofunginbusinessAgronomy and Crop Science
researchProduct

Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study

2003

Abstract Background. Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category. This might be useful to reduce the duration of anti-Helicobacter therapies. Aims. The aim of this study was to assess whether there is the possibility of shortening a rabeprazole-based triple therapy from 7 to 4 days without compromising its efficacy in the eradication of Helicobacter pylori infection. Patients. A total of 128 consecutive dyspeptic patients with H. pylori infection were recruited for this controlled, randomized, open and parallel-group trial comparing the efficacy of two durations of the same rabeprazole-based tr…

MalePeptic Ulcermedicine.medical_specialtymedicine.drug_classUrea breath testRabeprazoleProton-pump inhibitorPilot ProjectsGastroenterology2-PyridinylmethylsulfinylbenzimidazolesDrug Administration ScheduleHelicobacter InfectionsAnti-Infective AgentsClarithromycinMetronidazoleClarithromycinInternal medicinemedicineHumansProspective StudiesDyspepsiaAdverse effectHelicobacter pyloriHepatologybiologymedicine.diagnostic_testbusiness.industryGastroenterologyProton Pump InhibitorsMiddle AgedHelicobacter pyloriAnti-Ulcer Agentsbiology.organism_classificationAnti-Bacterial AgentsMetronidazoleRegimenTreatment OutcomeRabeprazoleBenzimidazolesDrug Therapy CombinationFemalebusinessOmeprazolemedicine.drug
researchProduct

Endoscopic hemostasis followed by preventive transarterial embolization in high-risk patients with bleeding peptic ulcer: 5-year experience

2019

Abstract Background Upper gastrointestinal bleeding (UGIB) due to peptic ulcer disease is one of the leading causes of death in patients with non-variceal bleeding, resulting in up to 10% mortality rate, and the patient group at high risk of rebleeding (Forrest IA, IB, and IIA) often requires additional therapy after endoscopic hemostasis. Preventive transarterial embolization (P-TAE) after endoscopic hemostasis was introduced in our institution in 2014. The aim of the study is an assessment of the intermediate results of P-TAE following primary endoscopic hemostasis in patients with serious comorbid conditions and high risk of rebleeding. Methods During the period from 2014 to 2018, a tota…

Malemedicine.medical_specialtyLeft gastric arteryTransarterial embolizationmedicine.medical_treatmentlcsh:SurgeryNon-variceal gastrointestinal bleeding030230 surgeryGastroduodenal artery03 medical and health sciences0302 clinical medicineRecurrencePreventivemedicine.arterymedicineHumansEmbolizationAgedAged 80 and overbusiness.industryMortality rateHemostasis Endoscopiclcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RD1-811lcsh:RC86-88.9Middle Agedmedicine.diseaseEmbolization TherapeuticSurgeryPeptic Ulcer HemorrhageTreatment OutcomeEmergency MedicineFemale030211 gastroenterology & hepatologySurgeryFresh frozen plasmaUpper gastrointestinal bleedingPacked red blood cellsRockall scorebusinessResearch ArticleWorld Journal of Emergency Surgery
researchProduct

Time pattern of gastric acidity in Barrett's esophagus.

1996

Increased gastroesophageal acid reflux is frequently found in patients with Barrett's esophagus, and it has been hypothesized that gastric acid hypersecretion could be an important factor aggravating the exposure of esophageal mucosa to acid and then contributing to the development of this disorder. The aim of the present study was to assess whether the circadian pattern of gastric acidity differs between refluxer patients with and without Barrett's esophagus and normal subjects. Continuous 24-hr gastric pH monitoring was performed in 119 healthy volunteers, 20 patients with Barrett's esophagus, 37 patients with moderate and 10 patients with severe reflux esophagitis without Barrett's esoph…

Malemedicine.medical_specialtyPhysiologyPopulationGastroenterologyGastric AcidBarrett EsophagusInternal medicinemedicineHumansEsophagusReflux esophagitiseducationEsophagitis PepticMonitoring Physiologiceducation.field_of_studybusiness.industryEsophageal diseaseStomachdigestive oral and skin physiologyGastroenterologyRefluxGastric Acidity DeterminationMiddle Agedmedicine.diseasedigestive system diseasesCircadian Rhythmmedicine.anatomical_structureBarrett's esophagusGastric acidFemalebusinessDigestive diseases and sciences
researchProduct